

## ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Runzhi Chen

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input type="checkbox"/> None	
3	Royalties or licenses	x <input type="checkbox"/> None	
4	Consulting fees	x <input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> ___ None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> ___ None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> ___ None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> ___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> ___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> ___ None	
11	Stock or stock options	<input checked="" type="checkbox"/> ___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> ___ None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: January 5, 2022 \_\_\_\_\_

Your Name: Liu Yang \_\_\_\_\_

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77 \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input type="checkbox"/> None	
3	Royalties or licenses	x <input type="checkbox"/> None	
4	Consulting fees	x <input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> ___ None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> ___ None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> ___ None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> ___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> ___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> ___ None	
11	Stock or stock options	<input checked="" type="checkbox"/> ___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> ___ None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: January 5, 2022 \_\_\_\_\_

Your Name: Sheng Hu \_\_\_\_\_

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77 \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input type="checkbox"/> None	
3	Royalties or licenses	x <input type="checkbox"/> None	
4	Consulting fees	x <input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x ___ None	
6	Payment for expert testimony	x ___ None	
7	Support for attending meetings and/or travel	x ___ None	
8	Patents planned, issued or pending	x ___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x ___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x ___ None	
11	Stock or stock options	x ___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x ___ None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Zhusheng Yin

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input type="checkbox"/> None	
3	Royalties or licenses	x <input type="checkbox"/> None	
4	Consulting fees	x <input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x ___ None	
6	Payment for expert testimony	x ___ None	
7	Support for attending meetings and/or travel	x ___ None	
8	Patents planned, issued or pending	x ___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x ___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x ___ None	
11	Stock or stock options	x ___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x ___ None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

x **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**



## ICMJJE DISCLOSURE FORM

Date: January 5, 2022 \_\_\_\_\_

Your Name: Yanli Nie \_\_\_\_\_

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77 \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input type="checkbox"/> None	
3	Royalties or licenses	x <input type="checkbox"/> None	
4	Consulting fees	x <input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x <input type="checkbox"/> None	
6	Payment for expert testimony	x <input type="checkbox"/> None	
7	Support for attending meetings and/or travel	x <input type="checkbox"/> None	
8	Patents planned, issued or pending	x <input type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x <input type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x <input type="checkbox"/> None	
11	Stock or stock options	x <input type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x <input type="checkbox"/> None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

x **I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Hongli Xu

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input type="checkbox"/> None	
3	Royalties or licenses	x <input type="checkbox"/> None	
4	Consulting fees	x <input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> ___ None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> ___ None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> ___ None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> ___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> ___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> ___ None	
11	Stock or stock options	<input checked="" type="checkbox"/> ___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> ___ None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: January 5, 2022 \_\_\_\_\_

Your Name: Yi Zhong \_\_\_\_\_

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77 \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input type="checkbox"/> None	
3	Royalties or licenses	x <input type="checkbox"/> None	
4	Consulting fees	x <input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x ___ None	
6	Payment for expert testimony	x ___ None	
7	Support for attending meetings and/or travel	x ___ None	
8	Patents planned, issued or pending	x ___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x ___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x ___ None	
11	Stock or stock options	x ___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x ___ None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: January 5, 2022 \_\_\_\_\_

Your Name: Yuze Zhu \_\_\_\_\_

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77 \_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input type="checkbox"/> None	
3	Royalties or licenses	x <input type="checkbox"/> None	
4	Consulting fees	x <input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> ___ None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> ___ None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> ___ None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> ___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> ___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> ___ None	
11	Stock or stock options	<input checked="" type="checkbox"/> ___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> ___ None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**



## ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Xinjun Liang

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input type="checkbox"/> None	
3	Royalties or licenses	x <input type="checkbox"/> None	
4	Consulting fees	x <input type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> ___ None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> ___ None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> ___ None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> ___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> ___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> ___ None	
11	Stock or stock options	<input checked="" type="checkbox"/> ___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> ___ None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Huiting Xu

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	x <input checked="" type="checkbox"/> None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	x <input checked="" type="checkbox"/> None	
3	Royalties or licenses	x <input checked="" type="checkbox"/> None	
4	Consulting fees	x <input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> ___ None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> ___ None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> ___ None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> ___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> ___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> ___ None	
11	Stock or stock options	<input checked="" type="checkbox"/> ___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> ___ None	
13	Other financial or non-financial interests	Jiangsu Hengrui Pharmaceutical Group Co. Ltd.	

**Please summarize the above conflict of interest in the following box:**

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**